“…The oncogenic role of miR-155 is well established in both hematological malignances as well as solid cancers such as breast cancer, where its overexpression is generally correlated with poor prognosis [ 357 , 358 ]. Validated miR-155 target genes are present in multiple pathways associated with cancer and cancer progression, including EMT ( SMAD5 ), proliferation ( SOCS1 , INPP5D , and CSF1R ), block of differentiation ( SPI1 , CEBPB ), and apoptosis ( CASP3 , FADD , APAF1 , and FOXO3A ) [ 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 ].…”